Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,167
archived clinical trials in
Liver Cancer

S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated:  3/12/2018
Charles F. Kettering Memorial Hospital
747
mi
from
Kettering, OH
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated: 3/12/2018
Charles F. Kettering Memorial Hospital
747
mi
from
Kettering, OH
Click here to add this to my saved trials
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated:  3/12/2018
St. Charles Mercy Hospital
806
mi
from
Oregon, OH
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated: 3/12/2018
St. Charles Mercy Hospital
806
mi
from
Oregon, OH
Click here to add this to my saved trials
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated:  3/12/2018
North Coast Cancer Care, Incorporated
842
mi
from
Sandusky, OH
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated: 3/12/2018
North Coast Cancer Care, Incorporated
842
mi
from
Sandusky, OH
Click here to add this to my saved trials
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated:  3/12/2018
St. Vincent Mercy Medical Center
805
mi
from
Toledo, OH
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated: 3/12/2018
St. Vincent Mercy Medical Center
805
mi
from
Toledo, OH
Click here to add this to my saved trials
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated:  3/12/2018
Medical University of Ohio Cancer Center
799
mi
from
Toledo, OH
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated: 3/12/2018
Medical University of Ohio Cancer Center
799
mi
from
Toledo, OH
Click here to add this to my saved trials
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated:  3/12/2018
CCOP - Toledo Community Hospital
803
mi
from
Toledo, OH
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated: 3/12/2018
CCOP - Toledo Community Hospital
803
mi
from
Toledo, OH
Click here to add this to my saved trials
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated:  3/12/2018
Natalie Warren Bryant Cancer Center at St. Francis Hospital
155
mi
from
Tulsa, OK
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated: 3/12/2018
Natalie Warren Bryant Cancer Center at St. Francis Hospital
155
mi
from
Tulsa, OK
Click here to add this to my saved trials
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated:  3/12/2018
Fox Chase Cancer Center - Philadelphia
1229
mi
from
Philadelphia, PA
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated: 3/12/2018
Fox Chase Cancer Center - Philadelphia
1229
mi
from
Philadelphia, PA
Click here to add this to my saved trials
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated:  3/12/2018
UPMC Cancer Centers
975
mi
from
Pittsburgh, PA
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated: 3/12/2018
UPMC Cancer Centers
975
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated:  3/12/2018
AnMed Cancer Center
874
mi
from
Anderson, SC
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated: 3/12/2018
AnMed Cancer Center
874
mi
from
Anderson, SC
Click here to add this to my saved trials
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated:  3/12/2018
CCOP - Upstate Carolina
903
mi
from
Spartanburg, SC
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated: 3/12/2018
CCOP - Upstate Carolina
903
mi
from
Spartanburg, SC
Click here to add this to my saved trials
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated:  3/12/2018
M. D. Anderson Cancer Center at University of Texas
572
mi
from
Houston, TX
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated: 3/12/2018
M. D. Anderson Cancer Center at University of Texas
572
mi
from
Houston, TX
Click here to add this to my saved trials
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated:  3/12/2018
Fredericksburg Oncology, Incorporated
1106
mi
from
Fredericksburg, VA
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated: 3/12/2018
Fredericksburg Oncology, Incorporated
1106
mi
from
Fredericksburg, VA
Click here to add this to my saved trials
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated:  3/12/2018
Columbia Basin Hematology
1236
mi
from
Kennewick, WA
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated: 3/12/2018
Columbia Basin Hematology
1236
mi
from
Kennewick, WA
Click here to add this to my saved trials
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated:  3/12/2018
Union Hospital of Cecil County
1189
mi
from
Elkton, MD
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated: 3/12/2018
Union Hospital of Cecil County
1189
mi
from
Elkton, MD
Click here to add this to my saved trials
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated:  3/12/2018
Regions Hospital - Cancer Care Center
554
mi
from
Saint Paul, MN
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Status: Enrolling
Updated: 3/12/2018
Regions Hospital - Cancer Care Center
554
mi
from
Saint Paul, MN
Click here to add this to my saved trials
A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer
A Phase 1/2 Study of BMS-986183 in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  3/15/2018
Local Institution
1179
mi
from
Los Angeles, CA
A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer
A Phase 1/2 Study of BMS-986183 in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 3/15/2018
Local Institution
1179
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer
A Phase 1/2 Study of BMS-986183 in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  3/15/2018
Local Institution
1254
mi
from
Ottawa,
A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer
A Phase 1/2 Study of BMS-986183 in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 3/15/2018
Local Institution
1254
mi
from
Ottawa,
Click here to add this to my saved trials
A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer
A Phase 1/2 Study of BMS-986183 in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  3/15/2018
Local Institution
1384
mi
from
Portland, OR
A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer
A Phase 1/2 Study of BMS-986183 in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 3/15/2018
Local Institution
1384
mi
from
Portland, OR
Click here to add this to my saved trials
Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery
A Phase II Trial of Dasatinib (BMS-354825) in Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  3/20/2018
University of Southern California - Norris
1168
mi
from
Los Angeles, CA
Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery
A Phase II Trial of Dasatinib (BMS-354825) in Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 3/20/2018
University of Southern California - Norris
1168
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
A Phase I/II, Open-label Study to Evaluate the Safety and Anti-tumor Effects of NV1020 Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-line Chemotherapy, in Patients With Colorectal Adenocarcinoma Metastatic to the Liver
Status: Enrolling
Updated:  3/21/2018
University of California, San Diego
1118
mi
from
San Diego, CA
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
A Phase I/II, Open-label Study to Evaluate the Safety and Anti-tumor Effects of NV1020 Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-line Chemotherapy, in Patients With Colorectal Adenocarcinoma Metastatic to the Liver
Status: Enrolling
Updated: 3/21/2018
University of California, San Diego
1118
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
A Phase I/II, Open-label Study to Evaluate the Safety and Anti-tumor Effects of NV1020 Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-line Chemotherapy, in Patients With Colorectal Adenocarcinoma Metastatic to the Liver
Status: Enrolling
Updated:  3/21/2018
Massachusetts General Hospital
1443
mi
from
Boston, MA
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
A Phase I/II, Open-label Study to Evaluate the Safety and Anti-tumor Effects of NV1020 Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-line Chemotherapy, in Patients With Colorectal Adenocarcinoma Metastatic to the Liver
Status: Enrolling
Updated: 3/21/2018
Massachusetts General Hospital
1443
mi
from
Boston, MA
Click here to add this to my saved trials
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
A Phase I/II, Open-label Study to Evaluate the Safety and Anti-tumor Effects of NV1020 Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-line Chemotherapy, in Patients With Colorectal Adenocarcinoma Metastatic to the Liver
Status: Enrolling
Updated:  3/21/2018
University of Pittsburgh Cancer Center
971
mi
from
Pittsburgh, PA
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
A Phase I/II, Open-label Study to Evaluate the Safety and Anti-tumor Effects of NV1020 Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-line Chemotherapy, in Patients With Colorectal Adenocarcinoma Metastatic to the Liver
Status: Enrolling
Updated: 3/21/2018
University of Pittsburgh Cancer Center
971
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
A Phase I/II, Open-label Study to Evaluate the Safety and Anti-tumor Effects of NV1020 Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-line Chemotherapy, in Patients With Colorectal Adenocarcinoma Metastatic to the Liver
Status: Enrolling
Updated:  3/21/2018
University of Vanderbilt
618
mi
from
Nashville, TN
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
A Phase I/II, Open-label Study to Evaluate the Safety and Anti-tumor Effects of NV1020 Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-line Chemotherapy, in Patients With Colorectal Adenocarcinoma Metastatic to the Liver
Status: Enrolling
Updated: 3/21/2018
University of Vanderbilt
618
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
A Phase I/II, Open-label Study to Evaluate the Safety and Anti-tumor Effects of NV1020 Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-line Chemotherapy, in Patients With Colorectal Adenocarcinoma Metastatic to the Liver
Status: Enrolling
Updated:  3/21/2018
Mary Crowley Medical Research Center
347
mi
from
Dallas, TX
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
A Phase I/II, Open-label Study to Evaluate the Safety and Anti-tumor Effects of NV1020 Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-line Chemotherapy, in Patients With Colorectal Adenocarcinoma Metastatic to the Liver
Status: Enrolling
Updated: 3/21/2018
Mary Crowley Medical Research Center
347
mi
from
Dallas, TX
Click here to add this to my saved trials
Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
A Phase II Study of GW572016 (Lapatanib) in Locally Advanced or Metastatic Hepato-Biliary Cancers
Status: Enrolling
Updated:  3/22/2018
UC Davis Comprehensive Cancer Center
1283
mi
from
Sacramento, CA
Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
A Phase II Study of GW572016 (Lapatanib) in Locally Advanced or Metastatic Hepato-Biliary Cancers
Status: Enrolling
Updated: 3/22/2018
UC Davis Comprehensive Cancer Center
1283
mi
from
Sacramento, CA
Click here to add this to my saved trials
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSphere®) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT)
Status: Enrolling
Updated:  3/28/2018
Northwestern Medical Faculty Foundation, Div of Hematology/Oncology
611
mi
from
Chicago, IL
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSphere®) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT)
Status: Enrolling
Updated: 3/28/2018
Northwestern Medical Faculty Foundation, Div of Hematology/Oncology
611
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSphere®) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT)
Status: Enrolling
Updated:  3/28/2018
Mount Sinai School of Medicine
1290
mi
from
New York, NY
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSphere®) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT)
Status: Enrolling
Updated: 3/28/2018
Mount Sinai School of Medicine
1290
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSphere®) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT)
Status: Enrolling
Updated:  3/28/2018
Cliniques Universitaires Saint-Luc
4719
mi
from
Brussels,
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSphere®) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT)
Status: Enrolling
Updated: 3/28/2018
Cliniques Universitaires Saint-Luc
4719
mi
from
Brussels,
Click here to add this to my saved trials
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Status: Enrolling
Updated:  3/29/2018
University of Colorado Cancer Center
402
mi
from
Aurora, CO
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Status: Enrolling
Updated: 3/29/2018
University of Colorado Cancer Center
402
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Status: Enrolling
Updated:  3/29/2018
Yale University, Yale Cancer Center
1344
mi
from
New Haven, CT
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Status: Enrolling
Updated: 3/29/2018
Yale University, Yale Cancer Center
1344
mi
from
New Haven, CT
Click here to add this to my saved trials
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Status: Enrolling
Updated:  3/29/2018
Laura and Isaac Permutter Cancer Center @ NYU Langone
1288
mi
from
New York, NY
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Status: Enrolling
Updated: 3/29/2018
Laura and Isaac Permutter Cancer Center @ NYU Langone
1288
mi
from
New York, NY
Click here to add this to my saved trials
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Status: Enrolling
Updated:  3/29/2018
The Ohio State University James Cancer Hospital
810
mi
from
Columbus, OH
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Status: Enrolling
Updated: 3/29/2018
The Ohio State University James Cancer Hospital
810
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Status: Enrolling
Updated:  3/29/2018
U.S.C./Norris Comprehensive Cancer Center
1166
mi
from
Los Angeles, CA
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Status: Enrolling
Updated: 3/29/2018
U.S.C./Norris Comprehensive Cancer Center
1166
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Status: Enrolling
Updated:  3/29/2018
Swedish Cancer Institute
1410
mi
from
Seattle, WA
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Status: Enrolling
Updated: 3/29/2018
Swedish Cancer Institute
1410
mi
from
Seattle, WA
Click here to add this to my saved trials
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
PET Imaging of Hepatocellular Carcinoma With 18F-FSPG
Status: Enrolling
Updated:  4/4/2018
Vanderbilt-Ingram Cancer Center
618
mi
from
Nashville, TN
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
PET Imaging of Hepatocellular Carcinoma With 18F-FSPG
Status: Enrolling
Updated: 4/4/2018
Vanderbilt-Ingram Cancer Center
618
mi
from
Nashville, TN
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
University of Alabama at Birmingham
676
mi
from
Birmingham, AL
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
University of Alabama at Birmingham
676
mi
from
Birmingham, AL
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
Greater Arkansas Veterans Healthcare
371
mi
from
Little Rock, AR
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
Greater Arkansas Veterans Healthcare
371
mi
from
Little Rock, AR
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
VA Greater Los Angeles Healthcare System
1177
mi
from
Los Angeles, CA
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
VA Greater Los Angeles Healthcare System
1177
mi
from
Los Angeles, CA
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
UCLA
1177
mi
from
Los Angeles, CA
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
UCLA
1177
mi
from
Los Angeles, CA
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
Palo Alto Veterans Institute for Research
1330
mi
from
Palo Alto, CA
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
Palo Alto Veterans Institute for Research
1330
mi
from
Palo Alto, CA
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
Stanford University
1329
mi
from
Stanford, CA
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
Stanford University
1329
mi
from
Stanford, CA
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
Georgetown University Hospital
1127
mi
from
Washington,
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
Georgetown University Hospital
1127
mi
from
Washington,
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
Tampa General Hospital
1117
mi
from
Tampa, FL
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
Tampa General Hospital
1117
mi
from
Tampa, FL
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
Northwestern University
611
mi
from
Chicago, IL
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
Northwestern University
611
mi
from
Chicago, IL
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
Massachusetts General Hospital
1443
mi
from
Boston, MA
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
Massachusetts General Hospital
1443
mi
from
Boston, MA
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
Albany Medical Center
1307
mi
from
Albany, NY
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
Albany Medical Center
1307
mi
from
Albany, NY
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
Mount Sinai Hospital
1289
mi
from
New York, NY
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
Mount Sinai Hospital
1289
mi
from
New York, NY
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
Hospital of the University of Pennsylvania
1223
mi
from
Philadelphia, PA
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
Hospital of the University of Pennsylvania
1223
mi
from
Philadelphia, PA
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
Albert Einstein Healthcare
1225
mi
from
Philadelphia, PA
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
Albert Einstein Healthcare
1225
mi
from
Philadelphia, PA
Click here to add this to my saved trials